Advisory Committee Policy Allows Members With Financial Conflicts To Vote
Executive Summary
FDA advisory committee participants with personal financial conflicts of interest may fully participate in committee meetings, according to the agency's new conflict of interest policy. The final guidance eliminates the draft provision that financial conflicts of any sort preclude an opportunity for panelists to vote
You may also be interested in...
CDER Advisory Committee Staffing Improves, But Trouble Spots Remain
After years of widespread vacancies on advisory committees, the Food & Drug Administration appears to have tackled most of the problems. But there are a couple of significant outliers, most significantly the Dermatology & Ophthalmic Products Advisory Committee. Will changes in conflict of interest rules and a new recruitment effort help FDA find and retain advisory committee members?
CDER Advisory Panel Vacancies Remain High As Overall FDA Rates Improve
Empty slots on CDER advisory panels holding agency back from meeting goal vacancy rate as other centers fill more panel slots.
Conflict Over Conflicts: FDA Advisory Committee Rules May Be Ripe For Change
Recruitment of FDA advisory committee members has been a persistent challenge for the agency—especially since the conflict of interest rules were tightened five years ago. While FDA has improved the number of vacancies on its expert panels, it has yet to meet its goals—especially in the Center for Drugs. Congress is considering loosening the restrictions. Will that help, or simply fuel criticism of the process?